GSK Velu
Healthcare
Stakeboat, now raising second fund, has a couple more arrows left in first-fund quiver
Mid-market private equity firm Stakeboat Capital, which hit the road last month to raise its second fund of Rs 1,000 ......
Finance
GSK Velu-backed Stakeboat Capital floats new fund
Stakeboat Capital, a mid-market private equity firm backed and launched by serial healthcare entrepreneur GSK Velu, has launched...
Healthcare
LGT Lightstone-backed Kauvery Hospital to make Bengaluru acquisition
Tamil Nadu-based hospital chain Kauvery Hospital, which received investment from impact investor LGT Lightstone Aspada last year,...
Healthcare
Coronavirus: Pathology chains wait on the sidelines, device makers gear up
The number of confirmed coronavirus cases (COVID-19), which was declared a pandemic by the World Health Organization (WHO) last...
Healthcare
Explained: How treating medical devices as ‘drugs' will affect companies, investors
From April, all medical devices sold in India will be treated as ‘drugs’. On Tuesday, the central government issued...
Healthcare
Trivitron tweaks IPO plan as it weighs exit options for PE investors
Medical devices maker Trivitron Healthcare Pvt. Ltd is considering the possibility of deferring its initial public offering plan...
Healthcare
Company watch: GSK Velu's Trivitron ramps up revenue, faces working-capital challenges
Trivitron Healthcare Pvt. Ltd, the medical equipment maker founded by serial entrepreneur GSK Velu, doubled the pace of growth...
Healthcare
Why hospital chains are still cool to Ayushman Bharat despite higher rates
The Centre's flagship health insurance scheme, which claims to have treated 45 lakh patients within a year of its launch ......
Healthcare
Sector watch: Can India's eye-care chains reverse a revenue slowdown?
When Singapore sovereign wealth fund Temasek Holdings came in as a new investor in Dr Agarwal’s Health Care Ltd earlier...
Healthcare
Tracing Carlyle's returns from partial exit in Metropolis' upcoming IPO
US-headquartered private equity giant The Carlyle Group appears likely to score modest returns from the sale of a little more...